A5064132655- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Multiple and Secondary Primary Cancers
- Viral Infectious Diseases and Gene Expression in Insects
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Biomedical Ethics and Regulation
- Integrated Circuits and Semiconductor Failure Analysis
- Cancer Treatment and Pharmacology
- Cutaneous lymphoproliferative disorders research
University Hospital Cologne
2016-2025
University of Cologne
2013-2025
Heinrich Heine University Düsseldorf
2019-2025
Düsseldorf University Hospital
2019-2025
Nordic Lymphoma Group
2025
German Inflammatory Bowel Diseases Study Group
2011-2024
Centrum für Integrierte Onkologie
2011-2023
Integrated Oncology (United States)
2019-2023
Hôpital 20 Août
2023
Copenhagen University Hospital
2023
Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets eliminates CD19-expressing B cells showed efficacy against lymphomas in single-center, phase 2a study.We conducted an international, 2, pivotal study of centrally manufactured involving adult patients who were ineligible for had disease progression...
Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted multicenter, randomized trial comparing four groups consisting combination chemotherapy regimen two different intensities followed by involved-field radiation therapy at dose levels.We randomly assigned 1370 patients newly diagnosed early-stage one groups: cycles doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)...
Romidepsin is a structurally unique, potent class 1 selective histone deacetylase inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).Patients who were at least one prior systemic therapy for whom failed received 14 mg/m(2) as 4-hour intravenous infusion on days 1, 8, and 15 every 28 days. end point rate complete response/unconfirmed...
Combined-modality treatment consisting of four to six cycles chemotherapy followed by involved-field radiotherapy (IFRT) is the standard care for patients with early unfavorable Hodgkin's lymphoma (HL). It unclear whether results can be improved more intensive and which radiation dose needs applied.Patients age 16 75 years newly diagnosed HL were randomly assigned in a 2 × factorial design one following arms: doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) + 30 Gy IFRT; ABVD 20...
In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor control approximately 80%. We aimed to improve these using more intensive chemotherapy.Patients newly diagnosed HL were randomly assigned either or an intensified consisting two escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine,...
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy is needed. Therefore, we analyzed gonadal functions survivors HL. Patients Methods Women younger than age 40 men 50 years at diagnosis ongoing remission least 1 year after within German Study Group HD13 to HD15 trials for early- advanced-stage HL were included. Hormone parameters, menstrual cycle, symptoms hypogonadism, offspring...
PURPOSE Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) small-field radiotherapy is standard of care for patients early-stage favorable Hodgkin lymphoma (HL). However, the role has been challenged. Positron emission tomography (PET) after (PET-2) might help to predict individual outcomes guide treatment. METHODS Between November 2009 December 2015, we recruited age 18 75 years newly diagnosed, HL this international randomized phase III...
In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated highly effective in relapsed/refractory cHL has not been adequately studied first-line treatment of cHL. The NIVAHL trial evaluated nivolumab this setting with the aim to develop a yet tolerable systemic ultimately mitigate morbidity patients who survive cHL.To evaluate efficacy 2 experimental nivolumab-based...
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating safety feasibility of chimeric receptor (CAR) T cells targeting CLDN6 with or without CAR-T cell-amplifying RNA vaccine (CARVac) at two levels (DLs) relapsed/refractory CLDN6-positive tumors. primary endpoints were tolerability, maximum tolerated recommended 2 (RP2D)....
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of within 24 months (POD24) from first-line immunochemotherapy or refractory to both CD20-targeting agent alkylator (double refractory), due no established standard care poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two more lines prior systemic therapy, but there consensus on its optimal timing the course...
MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the safety, maximum-tolerated dose (MTD), and efficacy patients with relapsed or refractory CD30+ lymphomas, sequential phase I II studies were performed.In portion, was administered intravenously at doses 0.1, 1, 5, 10 mg/kg weekly for 4 weeks to cohorts three six patients. Twenty-one patients--16 Hodgkin's lymphoma (HL),...
To determine the efficacy and safety of a newly developed concomitant administration fludarabine alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL).A total 36 were treated this phase II study (median age, 61.47 years; mean number prior chemotherapies, 2.6; Binet stage C, n = 28). After an initial dose escalation over 3 days, 30 mg mg/m2 administered on consecutive days. Treatment was repeated after 28 days for up to six cycles. Restaging...
Purpose Eight cycles of BEACOPP escalated (escalated dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by radiotherapy (RT) to initial bulk or residual tumor mass is the German Hodgkin Study Group standard care for advanced-stage Hodgkin's lymphoma (HL). However, treatment-related toxicity a concern, role RT in this setting unclear. The HD12 study thus aimed reduce while maintaining efficacy. Patients Methods In prospectively...